ARCHIVES

FDA Advisors Uphold Broad Mandate To Limit Use Of ESA Products In Cancer Indications.

This article is from The Cancer Letter archive.

Vol. 33 No. 18 | May 11, 2007

Download PDF Visit The Full Archive

Related Articles

White House Gives FDA Authority Over Tobacco Product Sales

August 18, 1995

Budget Process for FY ’81 Starts; Investigators Initiated Definition May Be Heated Issues

August 31, 1979

In Brief: All 77 New NCI Positions Go to Carcinogenesis Programs; “Not Wisest Way To Use Them” – Newell

February 4, 1977

Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease

December 28, 2012

FDA Approves Bayer’s Xofigo For Late-Stage Prostate Cancer

May 31, 2013

NCI Sends Letter To Grantees To Explain Tighter Funding.

March 16, 2001